Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relma-cel in R/R LBCL
NCT06479356Phase 2
Key facts
- Status
- Recruiting
- Start
- Aug 2024
- Primary completion
- Apr 2025
- Countries
- 1
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Conditions
- diffuse large B-cell lymphoma (DLBCL)
01
Overview
Phase 2, open-label, single-arm trial of relmacabtagene autoleucel in diffuse large B-cell lymphoma (DLBCL), sponsored by Shanghai Ming Ju Biotechnology. Primary endpoint: Objective Response Rate at 3 months. Started Aug 2024; status: recruiting.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Relma-cel
Relmacabtagene autoleucel 1 x 10^8 CAR+ T cells
03
Endpoints
Primary
Objective Response Rate
Secondary
Objective Response Rate
Best Objective Response Rate
Complete Response Rate
Progression-Free Survival
Overall Survival
Duration of Response
Pharmacokinetic Cmax
Pharmacokinetic Tmax
Beyond the preview
Go deeper on NCT06479356.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06479356.